Targeted deep sequencing in polycythemia vera and essential thrombocythemia-Reference-Cited by-同舟云学术

Targeted deep sequencing in polycythemia vera and essential thrombocythemia

Published:2016-11-22 Issue:1 Volume:1 Page:21-30
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Tefferi Ayalew¹,Lasho Terra L.¹,Guglielmelli Paola²,Finke Christy M.¹,Rotunno Giada²,Elala Yoseph¹,Pacilli Annalisa²,Hanson Curtis A.³,Pancrazzi Alessandro²,Ketterling Rhett P.⁴,Mannarelli Carmela²,Barraco Daniela¹,Fanelli Tiziana²,Pardanani Animesh¹,Gangat Naseema¹,Vannucchi Alessandro M.²

Affiliation:

1. Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN;

2. Centro Ricerca e Innovazione Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, and Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; and

3. Division of Hematopathology and

4. Division of Cytogenetics, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN

Abstract

Key Points More than half of patients with PV or ET harbor DNA mutations/variants other than JAK2/CALR/MPL. The presence of some of these mutations adversely affects overall, leukemia-free, or myelofibrosis-free survival.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/1/21/877387/advances000216.pdf

Reference24 articles.

1. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera;James;Nature,2005

2. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis;Scott;N Engl J Med,2007

3. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia;Pikman;PLoS Med,2006

4. Mutation in TET2 in myeloid cancers;Delhommeau;N Engl J Med,2009

5. Somatic mutations of calreticulin in myeloproliferative neoplasms;Klampfl;N Engl J Med,2013

Cited by 250 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What are the future prospects for polycythemia vera pharmacotherapies for patients with hydroxyurea resistance?;Expert Opinion on Pharmacotherapy;2024-08-12

2. IDH2 mutation accelerates TPO‐induced myelofibrosis with enhanced S100a8/a9 and NFκB signaling in vivo;eJHaem;2024-07-28

3. The evolving landscape of polycythemia vera therapies;Expert Opinion on Pharmacotherapy;2024-07-23

4. Immunofluorescence microscopy on the blood smear identifies patients with myeloproliferative neoplasms;Leukemia;2024-07-17

5. Clinical utility of investigations in triple‐negative thrombocytosis: A real‐world, multicentre evaluation of UK practice;British Journal of Haematology;2024-07-14